<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Aim Immunotech Inc. — News on 6ix</title>
    <link>https://6ix.com/company/aim-immunotech-inc-1</link>
    <description>Latest news and press releases for Aim Immunotech Inc. on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Mon, 13 Apr 2026 22:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/aim-immunotech-inc-1" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo69d7311051cc36e47532ce1f.webp</url>
      <title>Aim Immunotech Inc.</title>
      <link>https://6ix.com/company/aim-immunotech-inc-1</link>
    </image>
    <item>
      <title>AIM ImmunoTech Provides Routine Update on Annual Filings</title>
      <link>https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-provides-routine-update-on-annual-filings</link>
      <guid isPermaLink="true">https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-provides-routine-update-on-annual-filings</guid>
      <pubDate>Mon, 13 Apr 2026 22:00:00 GMT</pubDate>
      <description>OCALA, Fla., April 13, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today advised that its audited consolidated financial statements for the fiscal year ended December 31, 2025, contained an audit report from its independent registered public accounting firm with a going concern emphasis of matter. Release of this information is required by Section 610(b) of the NYSE American Company Guide, and does not represent any change or amendment to any of the</description>
    </item>
    <item>
      <title>AIM ImmunoTech to Participate in Live Virtual Investor Closing Bell Event</title>
      <link>https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event</link>
      <guid isPermaLink="true">https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-to-participate-in-live-virtual-investor-closing-bell-event</guid>
      <pubDate>Thu, 09 Apr 2026 12:00:00 GMT</pubDate>
      <description>Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, April 16th at 4:00 PM ET Register for the event here OCALA, Fla., April 09, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM, will participate in a Virtual Investor Closing Bell Event on Thursday, April 16, 2026, at 4:00 PM ET. Mr. Equels will provide a corporate overview and business out</description>
    </item>
    <item>
      <title>AIM ImmunoTech Announces Final Approval of Novel Cancer Therapy Patent in Japan Combining Ampligen with Checkpoint Inhibitors</title>
      <link>https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-announces-final-approval-of-novel-cancer-therapy-patent-in-japan-combining-ampligen-with-checkpoint-inhibitors</link>
      <guid isPermaLink="true">https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-announces-final-approval-of-novel-cancer-therapy-patent-in-japan-combining-ampligen-with-checkpoint-inhibitors</guid>
      <pubDate>Wed, 18 Mar 2026 12:36:00 GMT</pubDate>
      <description>AIM also intends to pursue Japanese Orphan Drug Designation for Ampligen in treatment of pancreatic cancerOCALA, Fla., March 18, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Japan Patent Office has fully approved a Japanese patent covering the Company’s proprietary use of Ampligen (rintatolimod) in combination with checkpoint inhibitors (anti-PD-1 or anti-PD-L1 antibodies) for the treatment of cancer. The patent was granted i</description>
    </item>
    <item>
      <title>AIM ImmunoTech Announces Closing of its Rights Offering</title>
      <link>https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-announces-closing-of-its-rights-offering-1</link>
      <guid isPermaLink="true">https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-announces-closing-of-its-rights-offering-1</guid>
      <pubDate>Sat, 07 Mar 2026 00:00:00 GMT</pubDate>
      <description>OCALA, Fla., March 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – announced today the closing of its previously announced rights offering (the “Rights Offering”). The Rights Offering resulted in total subscriptions of appr</description>
    </item>
    <item>
      <title>AIM ImmunoTech Announces Expiration and Preliminary Results of its Rights Offering for Aggregate Gross Proceeds of $1.8 Million</title>
      <link>https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-dollar18-million-61</link>
      <guid isPermaLink="true">https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-announces-expiration-and-preliminary-results-of-its-rights-offering-for-aggregate-gross-proceeds-of-dollar18-million-61</guid>
      <pubDate>Wed, 04 Mar 2026 14:00:00 GMT</pubDate>
      <description>OCALA, Fla., March 04, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced the preliminary results of its previously announced rights offering (the “Rights Offering”) which expired at 5:00 p.m., Eastern Time, on Mar</description>
    </item>
    <item>
      <title>AIM ImmunoTech Signs Agreement for Planning of a Proposed Phase 3 Clinical Trial of Ampligen in the Treatment of Late-Stage Pancreatic Cancer</title>
      <link>https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-signs-agreement-for-planning-of-a-proposed-phase-3-clinical-trial-of-ampligen-in-the-treatment-of-late-stage-pancreatic-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-signs-agreement-for-planning-of-a-proposed-phase-3-clinical-trial-of-ampligen-in-the-treatment-of-late-stage-pancreatic-cancer</guid>
      <pubDate>Mon, 02 Mar 2026 14:00:00 GMT</pubDate>
      <description>OCALA, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced an agreement with the PPD™ clinical research business of Thermo Fisher Scientific to design AIM’s anticipated Phase 3 clinical trial in the use of the Company’s drug Ampligen in the treatment of late-stage pancreatic cancer. AIM CEO Thomas K. Equels states: “The ongoing Phase 2 DURIPANC clinical trial of Ampligen and AstraZeneca’s durvalumab in the treatment of late-s</description>
    </item>
    <item>
      <title>AIM ImmunoTech Reminds Stockholders of March 3, 2026 Expiration Date and Updates Terms of Previously Announced Rights Offering</title>
      <link>https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-reminds-stockholders-of-march-3-2026-expiration-date-and-updates-terms-of-previously-announced-rights-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-reminds-stockholders-of-march-3-2026-expiration-date-and-updates-terms-of-previously-announced-rights-offering</guid>
      <pubDate>Fri, 27 Feb 2026 14:00:00 GMT</pubDate>
      <description>OCALA, Fla., Feb. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced updated terms for its previously announced rights offering (the “Rights Offering”). Each subscription right now entitles holders to purchase</description>
    </item>
    <item>
      <title>AIM ImmunoTech Announces Extension of Subscription Period of its Previously Announced Rights Offering to March 3, 2026</title>
      <link>https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-announces-extension-of-subscription-period-of-its-previously-announced-rights-offering-to-march-3-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-announces-extension-of-subscription-period-of-its-previously-announced-rights-offering-to-march-3-2026</guid>
      <pubDate>Wed, 25 Feb 2026 14:00:00 GMT</pubDate>
      <description>OCALA, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – announced today that it has extended the subscription period of its previously announced rights offering until 5:00 p.m., Eastern Time, on Tuesday, March 3,</description>
    </item>
    <item>
      <title>AIM ImmunoTech Announces Planned Milestones in the Ongoing Phase 2 Trial of Ampligen and AstraZeneca’s Durvalumab in the Treatment of Metastatic Pancreatic Cancer</title>
      <link>https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-announces-planned-milestones-in-the-ongoing-phase-2-trial-of-ampligen-and-astrazenecas-durvalumab-in-the-treatment-of-metastatic-pancreatic-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-announces-planned-milestones-in-the-ongoing-phase-2-trial-of-ampligen-and-astrazenecas-durvalumab-in-the-treatment-of-metastatic-pancreatic-cancer</guid>
      <pubDate>Mon, 23 Feb 2026 13:55:00 GMT</pubDate>
      <description>OCALA, Fla., Feb. 23, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced milestones in the expected timeline for the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen® (rintatolimod) combined with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of metastatic pancreatic cancer patients with stable disease post-FOLFIRINOX standard of care (the “DURIPANC” study) (see: ClinicalTrials.gov N</description>
    </item>
    <item>
      <title>CORRECTION: AIM ImmunoTech Announces Commencement of Rights Offering</title>
      <link>https://6ix.com/company/aim-immunotech-inc-1/news/correction-aim-immunotech-announces-commencement-of-rights-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/aim-immunotech-inc-1/news/correction-aim-immunotech-announces-commencement-of-rights-offering</guid>
      <pubDate>Thu, 12 Feb 2026 21:35:00 GMT</pubDate>
      <description>This press release is issued solely to correct a date from an AIM press release dated February 11, 2026. The Subscription Rights will expire if they are not exercised by 5:00 p.m., Eastern Time, on February 27, 2026, the expected expiration date of the Rights Offering. OCALA, Fla., Feb. 12, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen</description>
    </item>
    <item>
      <title>AIM ImmunoTech Announces Commencement of Rights Offering</title>
      <link>https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-announces-commencement-of-rights-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-announces-commencement-of-rights-offering</guid>
      <pubDate>Wed, 11 Feb 2026 13:30:00 GMT</pubDate>
      <description>OCALA, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of its lead product, Ampligen® (rintatolimod), for the treatment of late-stage pancreatic cancer – a lethal and unmet global health problem – today announced that it has commenced its previously disclosed rights offering (the “Rights Offering”). Pursuant to the Rights Offering, the Company is distr</description>
    </item>
    <item>
      <title>AIM ImmunoTech to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial</title>
      <link>https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-to-participate-in-the-corporate-connect-webinar-series-virtual-conference-hosted-by-webull-financial</link>
      <guid isPermaLink="true">https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-to-participate-in-the-corporate-connect-webinar-series-virtual-conference-hosted-by-webull-financial</guid>
      <pubDate>Fri, 06 Feb 2026 13:55:00 GMT</pubDate>
      <description>Live video webcast on Wednesday, February 11th at 1:40 PM EST OCALA, Fla., Feb. 06, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today that it will participate in the Corporate Connect Webinar Series hosted by Webull Financial being held virtually February 10-11, 2026. As part of the event, Thomas K. Equels, MS JD, Chief Executive Officer of AIM, will provide a corporate overview and business outlook and will focus on AIM’s strategic emphasis on pan</description>
    </item>
    <item>
      <title>AIM ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer</title>
      <link>https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-reports-positive-year-end-interim-clinical-progress-from-phase-2-study-evaluating-ampligenr-rintatolimod-in-combination-with-astrazenecas-imfinzir-durvalumab-for-the-treatment-of-pancreatic-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-reports-positive-year-end-interim-clinical-progress-from-phase-2-study-evaluating-ampligenr-rintatolimod-in-combination-with-astrazenecas-imfinzir-durvalumab-for-the-treatment-of-pancreatic-cancer</guid>
      <pubDate>Thu, 05 Feb 2026 13:40:00 GMT</pubDate>
      <description>Year-end report discusses combination therapy’s Mechanism of Action activating both innate and adaptive immune responsesOCALA, Fla., Feb. 05, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today reported positive data in a year-end update from the ongoing Phase 2 clinical study evaluating AIM’s drug Ampligen® (rintatolimod) combined with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) in the treatment of metastatic pancreatic</description>
    </item>
    <item>
      <title>AIM ImmunoTech Announces Changes to Key Dates and Terms Related to Announced Rights Offering</title>
      <link>https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-announces-changes-to-key-dates-and-terms-related-to-announced-rights-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-announces-changes-to-key-dates-and-terms-related-to-announced-rights-offering</guid>
      <pubDate>Tue, 27 Jan 2026 21:35:00 GMT</pubDate>
      <description>OCALA, Fla., Jan. 27, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, announced today changes to the previously announced key dates relating to its proposed rights offering (the “Rights Offering”). Except as expressly amended herein, the terms of the Rights Offering remain unchan</description>
    </item>
    <item>
      <title>AIM ImmunoTech Announces Key Dates and Terms Related to Announced Rights Offering</title>
      <link>https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-announces-key-dates-and-terms-related-to-announced-rights-offering</link>
      <guid isPermaLink="true">https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-announces-key-dates-and-terms-related-to-announced-rights-offering</guid>
      <pubDate>Fri, 23 Jan 2026 18:22:00 GMT</pubDate>
      <description>OCALA, Fla., Jan. 23, 2026 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) – AIM ImmunoTech Inc. (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, announced today an informational update to its security holders regarding its proposed rights offering (the “Rights Offering”) and the expected key dates and terms relative to the Rights Offering. Assuming that</description>
    </item>
    <item>
      <title>AIM ImmunoTech Announces Stock Dividend</title>
      <link>https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-announces-stock-dividend</link>
      <guid isPermaLink="true">https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-announces-stock-dividend</guid>
      <pubDate>Tue, 30 Dec 2025 22:10:00 GMT</pubDate>
      <description>OCALA, Fla., Dec. 30, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced a stock dividend of one share of common stock for every 1,000 shares of outstanding common stock as well as one share of common stock for every outstanding option or warrant that has a right to receive stock dividends (“Alternate Securities”). The dividend will be issuable to stockholders and Alternate Securities holders of record at the close of business on January 9,</description>
    </item>
    <item>
      <title>AIM ImmunoTech Announces Release of the Next CEO Corner Segment</title>
      <link>https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-announces-release-of-the-next-ceo-corner-segment</link>
      <guid isPermaLink="true">https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-announces-release-of-the-next-ceo-corner-segment</guid>
      <pubDate>Wed, 10 Dec 2025 14:00:00 GMT</pubDate>
      <description>Tom Equels, CEO of AIM ImmunoTech, discusses the unmet need and driving Ampligen forward in pancreatic cancerOCALA, Fla., Dec. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the next CEO Corner segment has been published on the Company’s website. In this latest CEO Corner segment, AIM Chief Executive Officer Thomas Equels discusses the unmet need in pancreatic cancer and the Company’s lead program, Ampligen® (rintatolimod), and its</description>
    </item>
    <item>
      <title>AIM ImmunoTech to Participate in Live ‘Fireside’ Chat on Virtual Investor Closing Bell Series</title>
      <link>https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-to-participate-in-live-fireside-chat-on-virtual-investor-closing-bell-series</link>
      <guid isPermaLink="true">https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-to-participate-in-live-fireside-chat-on-virtual-investor-closing-bell-series</guid>
      <pubDate>Mon, 01 Dec 2025 13:55:00 GMT</pubDate>
      <description>Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Thursday, December 4th at 4:00 PM ETOCALA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Closing Bell Series on Thursday, December 4, 2025 at 4:00 PM ET. As part of the event, Equels will participate in a moderated “fireside” chat that will</description>
    </item>
    <item>
      <title>AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program</title>
      <link>https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-reports-third-quarter-2025-financial-results-and-highlights-continued-progress-across-pipeline-with-strategic-focus-on-pancreatic-cancer-clinical-program</link>
      <guid isPermaLink="true">https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-reports-third-quarter-2025-financial-results-and-highlights-continued-progress-across-pipeline-with-strategic-focus-on-pancreatic-cancer-clinical-program</guid>
      <pubDate>Tue, 18 Nov 2025 13:55:00 GMT</pubDate>
      <description>OCALA, Fla., Nov. 18, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today provided a business update and reported its financial results for the third quarter 2025. “The third quarter was marked by solid and positive clinical and operational execution. Our clinical, manufacturing and regulatory teams are heavily focused on moving Ampligen down a pathway toward eventual FDA approval as part of a combination therapy for pancreatic cancer. We recently re</description>
    </item>
    <item>
      <title>AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen’s Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer</title>
      <link>https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-details-new-upmc-abstract-on-completed-clinical-trial-involving-ampligens-synergistic-potential-in-the-treatment-of-advanced-recurrent-ovarian-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/aim-immunotech-inc-1/news/aim-immunotech-details-new-upmc-abstract-on-completed-clinical-trial-involving-ampligens-synergistic-potential-in-the-treatment-of-advanced-recurrent-ovarian-cancer</guid>
      <pubDate>Mon, 10 Nov 2025 13:55:00 GMT</pubDate>
      <description>OCALA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today detailed a recent abstract containing data from the completed Phase 2 advanced recurrent ovarian cancer clinical study utilizing Ampligen (rintatolimod), which was presented at the 40th Annual SITC Meeting on November 7, 2025, at National Harbor, MD. Platinum-sensitive patients with measurable peritoneal disease were eligible for combination therapy with up to six treatment cycl</description>
    </item>
  </channel>
</rss>